Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Lumipulse plasma p‐tau217 measurements, on (A) a linear scale and (B) a log10 scale, in renal function impairment samples (from the CN‐CKD cohort including samples at CKD stage 1 [ n = 11], stage 2 [ n = 15], stage 3a [ n = 16], stage 3b [ n = 9], stage 4 [ n = 7]) compared to AD and non‐AD samples (from the CSF cohort with AD [ n = 159], and non‐AD [ n = 98], box plots show median ± IQR; dotted lines represent the 0.153 and 0.422 pg/mL p‐tau217 cut‐points derived from the CSF cohort, P < 0.001 **** using a Wilcoxon signed‐rank test). AD, Alzheimer's disease; CN‐CKD, cognitively normal‐chronic kidney disease; CSF, cerebrospinal fluid; IQR, interquartile range; p‐tau, phosphorylated tau

Article Snippet: Four experiments assessing the effects of varied pre‐analytical sampling conditions on relative plasma p‐tau217 concentrations were undertaken using both the Lumipulse and ALZpath assays.

Techniques: Clinical Proteomics, Derivative Assay

Journal: Alzheimer's & Dementia

Article Title: The Alzheimer's Disease Diagnosis and Plasma Phospho‐Tau217 (ADAPT) study stage 1: Validating clinical cut‐points against CSF and amyloid PET

doi: 10.1002/alz.71147

Figure Lengend Snippet: Relative change in concentration of plasma p‐tau217 across pre‐analytical sample handling conditions: (A) pre‐centrifugation delay at RT, (B) pre‐centrifugation delay at 2 to 8°C, (C) post‐centrifugation delay, (D) number of freeze–thaw cycles, compared to the baseline condition using the ALZpath and Lumipulse assays ( n = 10 per experiment, data presented as median ± IQR, dotted lines represent the lower and upper bounds of a 10% difference threshold from the baseline condition). IQR, interquartile range; p‐tau, phosphorylated tau; RT, room temperature

Article Snippet: Four experiments assessing the effects of varied pre‐analytical sampling conditions on relative plasma p‐tau217 concentrations were undertaken using both the Lumipulse and ALZpath assays.

Techniques: Concentration Assay, Clinical Proteomics, Analytical Sample Preparation, Centrifugation